SciTransfer
Organization

Servicio Vasco de Salud Osakidetza

Basque Country's public health service, providing real-world clinical validation environments for digital health, chronic care, and precision medicine innovations.

Public health servicehealthES
H2020 projects
18
As coordinator
0
Total EC funding
€2.5M
Unique partners
267
What they do

Their core work

Osakidetza is the public health service of the Basque Country (Spain), operating as the region's primary healthcare provider with a network of hospitals, health centers, and specialized care units. In H2020 projects, they contribute real-world clinical environments, patient cohorts, and healthcare professional expertise — serving as a living lab where digital health tools, rehabilitation platforms, and chronic disease management systems are tested with actual patients. Their involvement spans from validating e-health platforms and clinical decision support systems to piloting infection prevention protocols in neonatal intensive care. They are a demand-side partner: they don't build the technology, but they define clinical needs, test solutions in practice, and validate outcomes in operational healthcare settings.

Core expertise

What they specialise in

Chronic disease management and integrated careprimary
6 projects

Central theme across C3-Cloud, MIDAS, vCare, GATEKEEPER, ADLIFE, and Carematrix PCP — all focused on multimorbidity, elderly care, and personalized care platforms.

Digital health and patient empowerment platformsprimary
5 projects

Projects like MAGIC, STARR, GATEKEEPER, and ADLIFE focus on mobile self-care tools, virtual coaching, and personalized empowerment platforms for patients.

Health data security and privacysecondary
3 projects

SHiELD addressed secure health data exchange and consent management; SOTERIA tackles personal data protection and anonymization; privacy by design is a recurring theme.

Precision health and health technology assessmentemerging
1 project

ExACT (2019-2024) focuses on integrating precision health into care systems, covering big data, citizen engagement, and health technology assessment — a newer strategic direction.

Infection prevention in clinical settingsemerging
1 project

NeoIPC (2021-2026) addresses infection prevention of resistant bacteria in neonatal intensive care units through cluster randomized trials.

Pre-commercial procurement for health innovationsecondary
2 projects

Carematrix PCP and TBMED involve procurement-driven innovation — testing beds for medical devices and PCP for integrated care solutions.

Evolution & trajectory

How they've shifted over time

Early focus
E-health and rehabilitation tools
Recent focus
Precision health system integration

In their early H2020 period (2016–2018), Osakidetza focused on foundational e-health infrastructure: secure health data exchange, mobile rehabilitation tools for stroke survivors, and federated care architectures for multi-morbidity. From 2019 onward, their focus shifted decisively toward precision health, large-scale deployment of personalized care platforms, and pre-commercial procurement — indicating a move from piloting individual tools to system-wide integration of digital health into routine clinical practice. The appearance of infection prevention (NeoIPC) and personal data protection (SOTERIA) in their most recent projects signals a broadening beyond chronic disease into acute care and regulatory compliance.

Osakidetza is transitioning from testing individual digital health tools to deploying integrated, data-driven care systems at scale — making them an increasingly valuable validation partner for mature health technologies ready for real-world implementation.

Collaboration profile

How they like to work

Role: third_party_expertReach: European32 countries collaborated

Osakidetza never coordinates H2020 projects — they consistently join as a participant or third party, reflecting their role as a clinical end-user rather than a research leader. They operate in large consortia (267 unique partners across 32 countries), which is typical for health innovation projects requiring multi-site clinical validation. Their frequent third-party status (9 of 18 projects) suggests they are often brought in specifically to provide clinical testing environments and patient access, rather than driving the research agenda — a valuable but specialized role.

With 267 unique consortium partners across 32 countries, Osakidetza has a broad European network concentrated in health and digital innovation consortia. Their geographic reach spans most of the EU, though their Basque Country base gives them particularly strong ties to Spanish and Southern European health systems.

Why partner with them

What sets them apart

Osakidetza offers something most technology developers struggle to find: a large, operational public health system willing to serve as a real-world testing ground for digital health innovations. Unlike university hospitals that participate primarily for research output, Osakidetza brings the perspective of a regional health authority responsible for actual patient care delivery — meaning solutions validated with them face genuine operational constraints. For consortium builders, they provide clinical sites, patient cohorts, practitioner feedback, and the credibility of a public health system endorsement.

Notable projects

Highlights from their portfolio

  • GATEKEEPER
    Largest single EC contribution (EUR 634,978) — a major smart living and health risk detection demonstrator, indicating Osakidetza's strongest commitment as a validation site.
  • NeoIPC
    Their most recent active project (2021-2026) targeting antibiotic-resistant infections in neonatal ICUs — a departure from their usual chronic care focus, showing expansion into acute clinical challenges.
  • SHiELD
    Directly addressed the critical infrastructure layer of health data security and consent management — a foundational project that connects to their later work on data-driven precision health.
Cross-sector capabilities
Digital health and ICT validationData privacy and security in clinical contextsMedical device testing and pre-commercial procurementElderly care and social risk intervention
Analysis note: Osakidetza's high third-party participation rate (9 of 18 projects) means much of their involvement comes with no direct EC funding, making their actual engagement depth harder to assess from funding data alone. Their real value lies in clinical access rather than research output, which the project data supports but cannot fully quantify.